eli lilly retatrutide trials orforglipron oral GLP-1 phase 3 weight loss trial Eli Lilly says next-generation weight

As a result, some physicians may prescribe either for weight management

Retatrutide is not yet available in the UK and has not been approved for use by any regulatory bodies it is still undergoing clinical trials to assess its safety and effectiveness

It blocks the secretion of glucagon (a hormone that increases blood sugar), preventing blood sugar spikes

Patients with higher baseline body mass index (BMI) or more severe insulin resistance may experience different response patterns compared to those with milder metabolic dysfunction

& Herman, L

Studies have also suggested beneficial effects on inflammation and blood vessel function, two factors increasingly recognized as important contributors to cardiovascular disease.[14][18] Instead of targeting a single problem, GLP-1 medicines appear to influence several risk factors at once